Ana T. Nunes

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

Bradley J. Monk, Takafumi Toita, Xiaohua Wu et al. · The Lancet Oncology · 2023 · 182 citations

Advanced Cervical Cancer, Cervical Cancer Management, Cervical Cancer +10

BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

Peter Schmid, Seock‐Ah Im, Anne Armstrong et al. · Journal of Clinical Oncology · 2021 · 105 citations

Poor Clinical Outcomes, Breast Oncology, Immunology +23

CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study

Jyoti Mayadev, Ana T. Nunes, Mary Li et al. · International Journal of Gynecological Cancer · 2020 · 87 citations · Full text

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

Patrick Schmid, K.H. Jung, Piotr J. Wysocki et al. · Annals of Oncology · 2022 · 43 citations

Breast Oncology, Initial Results, Medicine +11

Monocyte and interferon based therapy for the treatment of ovarian cancer

Daniel S. Green, Ana T. Nunes, Christina M. Annunziata et al. · Cytokine & Growth Factor Reviews · 2016 · 33 citations · Full text

Medicine, Immunology, Gynecology +7